MX2023002002A - Proteinas de union restringidas activadas de forma condicional. - Google Patents

Proteinas de union restringidas activadas de forma condicional.

Info

Publication number
MX2023002002A
MX2023002002A MX2023002002A MX2023002002A MX2023002002A MX 2023002002 A MX2023002002 A MX 2023002002A MX 2023002002 A MX2023002002 A MX 2023002002A MX 2023002002 A MX2023002002 A MX 2023002002A MX 2023002002 A MX2023002002 A MX 2023002002A
Authority
MX
Mexico
Prior art keywords
tumor
constrained
binding proteins
activated binding
conditionally activated
Prior art date
Application number
MX2023002002A
Other languages
English (en)
Spanish (es)
Inventor
Tseng- Hui Timothy Chen
Chad Michael May
Robert B Dubridge
Patricia A Culp
Danielle Dettling
Jeremiah Degenhardt
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2023002002A publication Critical patent/MX2023002002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023002002A 2020-08-17 2021-08-17 Proteinas de union restringidas activadas de forma condicional. MX2023002002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063066565P 2020-08-17 2020-08-17
PCT/US2021/046217 WO2022040128A2 (en) 2020-08-17 2021-08-17 Constrained conditionally activated binding proteins

Publications (1)

Publication Number Publication Date
MX2023002002A true MX2023002002A (es) 2023-07-06

Family

ID=77655705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002002A MX2023002002A (es) 2020-08-17 2021-08-17 Proteinas de union restringidas activadas de forma condicional.

Country Status (16)

Country Link
US (1) US20240026011A1 (enExample)
EP (1) EP4196503A2 (enExample)
JP (1) JP7832926B2 (enExample)
KR (1) KR20230048146A (enExample)
CN (1) CN116419925A (enExample)
AR (1) AR123266A1 (enExample)
AU (1) AU2021329290A1 (enExample)
CA (1) CA3191431A1 (enExample)
CL (1) CL2023000477A1 (enExample)
CO (1) CO2023002164A2 (enExample)
EC (1) ECSP23018458A (enExample)
IL (1) IL300598A (enExample)
MX (1) MX2023002002A (enExample)
PE (1) PE20230856A1 (enExample)
TW (1) TW202214707A (enExample)
WO (1) WO2022040128A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
AR128593A1 (es) * 2022-02-23 2024-05-22 Takeda Pharmaceuticals Co Proteínas de unión condicionalmente biespecíficas
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
KR20250057869A (ko) * 2022-09-07 2025-04-29 잭세라 바이오파마슈티컬 (수조우) 씨오., 엘티디. 항-trop2/egfr 항체 및 이의 용도
CN120835898A (zh) * 2023-01-05 2025-10-24 哈珀恩治疗公司 用于治疗癌症的trop2靶向三特异性蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141522A1 (es) 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
CN109071667A (zh) 2016-03-08 2018-12-21 马弗里克治疗公司 可诱导性结合蛋白和使用方法
CN111356700A (zh) * 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
EP4592313A3 (en) * 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Also Published As

Publication number Publication date
WO2022040128A3 (en) 2022-04-07
EP4196503A2 (en) 2023-06-21
CN116419925A (zh) 2023-07-11
IL300598A (en) 2023-04-01
AR123266A1 (es) 2022-11-16
CL2023000477A1 (es) 2023-11-10
JP2023538366A (ja) 2023-09-07
ECSP23018458A (es) 2023-04-28
CA3191431A1 (en) 2022-02-24
JP7832926B2 (ja) 2026-03-18
KR20230048146A (ko) 2023-04-10
PE20230856A1 (es) 2023-05-29
WO2022040128A2 (en) 2022-02-24
CO2023002164A2 (es) 2023-03-07
AU2021329290A1 (en) 2023-04-13
TW202214707A (zh) 2022-04-16
US20240026011A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MX2023002002A (es) Proteinas de union restringidas activadas de forma condicional.
ZA202304893B (en) Constrained conditionally activated binding proteins
EP4592313A3 (en) Constrained conditionally activated binding proteins
WO2022051647A3 (en) Constrained conditionally activated binding protein constructs with human serum albumin domains
WO2021018859A3 (en) Antibodies binding to gprc5d
WO2021163064A3 (en) Antibodies and fusion proteins that bind to ccr8 and uses thereof
EA202192566A1 (ru) МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
BR112023011782A2 (pt) Proteínas de ligação condicionalmente biespecíficas
PH12023500005A1 (en) Multi-specific antigen binding molecules targeting hiv and methods of use
WO2022197890A8 (en) Anti-alpp/alppl2 antibodies and antibody-drug conjugates
WO2023079102A3 (en) Novel peptides
MX2024009292A (es) Anticuerpos anti-her2/trop2 y usos de los mismos.
WO2022082030A3 (en) Antigen-binding proteins and related methods of use
WO2022049220A3 (en) Antibody therapy
MX2023011777A (es) Métodos terapéuticos que usan proteínas de unión activadas condicionalmente restringidas.
WO2023023489A3 (en) Bispecific anti-flt3/cd3 antibodies and methods of use
EA202090671A1 (ru) Ограниченные условно активируемые связывающие белки
MX2024012404A (es) Composiciones y metodos para el tratamiento del cancer
WO2025188136A8 (en) Anti-tigit/anti-4-1bb bispecific antibodies and uses thereof
MX2025011554A (es) Proteinas de union a trop2 y usos de estas
WO2022256506A3 (en) Dkk1/hla-a2 binding molecules and methods of their use
MX2026001044A (es) Anticuerpos de union a citocina 1a similar al factor de necrosis tumoral (tnf) (tl1a) y metodos de uso
WO2022212682A3 (en) Methods and materials for targeting tumor antigens
AR118522A1 (es) Moléculas de unión cd3